Subclinical Myocardial Fibrosis in South African Youth With HIV: Results From the CTAAC-Heart Study

• Published in: Open forum infectious diseases 2024-10, Vol.11 (10), p.ofae555
• Main Authors: Jao, Jennifer, Zar, Heather J, Kahts, Morné, Jermy, Stephen, Egan, Daniel, Nyathi, Mothabisi N, Asafu-Agyei, Nana Akua, Legbedze, Justine, Carkeek, Emma, Jele, Nomawethu, Mautsa, Tafadzwa, Bonner, Lauren Balmert, McComsey, Grace A, Feinstein, Matthew, Kurland, Irwin J, Myer, Landon, Ntusi, Ntobeko A B
• Format: Article
• Language: English
• Subjects: Infectious Diseases in Special Populations
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofae555

Few data exist on myocardial fibrosis and inflammation in youth with HIV. We performed cardiovascular magnetic resonance (CMR) on a cross section of South African youth: youth with perinatally acquired HIV (YPHIV) undergoing antiretroviral therapy (ART), youth with nonperinatally acquired HIV (YNPHIV) receiving ART, and youth without HIV. Quantile regression models were fit to assess the association between HIV status and CMR outcomes: subclinical fibrosis (late gadolinium enhancement [LGE] mass and fraction, native T1, extracellular volume) and inflammation (native T1, T2 mapping). Of 464 youth, 287 were YPHIV, 87 were YNPHIV, and 90 were HIV seronegative. The median age was 16 years (range, 11-24). LGE mass was higher in YPHIV and YNPHIV than in youth who were HIV seronegative (1.85 vs 2.00 vs 1.41 g, respectively), as was fraction (5.8% vs 6.4% vs 4.5%); native T1 was highest in YNPHIV. In adjusted analyses, when compared with youth with HIV seronegativity, YPHIV and YNPHIV exhibited higher LGE mass (β = 0.468, = .001; β = 0.544, = .002) and LGE fraction (β = 1.587, < .001; β = 1.781, < .001). CMR outcomes were similar between YPHIV and YNPHIV. Despite ART use, YPHIV and YNPHIV appear to have higher subclinical myocardial fibrosis than youth who are HIV seronegative and healthy adults in South Africa and may benefit from early screening/monitoring for cardiovascular disease.